Navigation Links
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
Date:5/29/2009

the study includes patients being administered neratinib (160 mg or 240 mg) daily plus weekly trastuzumab (4 mg/kg IV loading dose then 2 mg/kg). In the second part of the study, patients receive a weekly dose of trastuzumab with daily neratinib (240 mg).

To date, 45 patients have been enrolled and 28 patients were evaluable for efficacy. The 16-week PFS rate (for part 2) was 45 percent (95 percent CI, 26 percent to 62 percent); median PFS was 16 weeks (95 percent CI, 15 to 31 weeks). The complete response rate was 7 percent, while 21 percent of evaluable patients showed partial response. The objective response rate was 29 percent (95 percent CI, 13 percent to 49 percent).

In this study, adverse events of any grade were diarrhea, nausea, anorexia, vomiting, asthenia, rash and fatigue. In the 45 patients enrolled in this study, diarrhea was the most common adverse event, observed in 91 percent of patients, and was the most significant grade 3 or 4 adverse event, occurring in 16 percent of patients. Two patients receiving neratinib 240 mg reported adverse events leading to discontinuation of therapy.

Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in Patients with Solid Tumors

In a separate phase 1/2, open-label, 2-part study, ascending multiple daily oral doses of neratinib (160 mg, 240 mg) were administered in combination with IV paclitaxel 80 mg/m2, if tolerable, or 70 mg/m2 on days 1, 8 and 15. Patients with solid tumors (endometrial, cervical, colorectal and esophageal cancers) were entered in the phase 1 portion (part 1), and only patients with metastatic ErbB-2 positive breast cancer were enrolled in part 2. Safety and efficacy were investigated in patients with ErbB-2 positive metastatic breast cancer.

A total of 102 patients were enrolled in part 2 of the study and 97 patients were evaluable for efficacy. The overall
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
2. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
3. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
4. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
5. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
6. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
7. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
10. What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/9/2014)... findings from Fox Chase Cancer Center paint a relatively ... of breast cancers that have spread to the chest ... that grow into the skin, regardless of size and ... as stage III and called "locally advanced" tumors, ... cancer, often with poor survival. Locally advanced breast cancers ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... There has been a sharp increase in the number ... MyChart, the online, interactive service that allows patients to ... providers, schedule appointments, and renew prescriptions. , Over a ... MyChart each year increased five-fold, while the number ... according to a study by Dr. David Gerber ...
(Date:7/9/2014)... world have been linked to an emerging fungal ... National Institute for Mathematical and Biological Synthesis (NIMBioS) ... , In a series of mathematical models, ... of internal organs in frogs, could cause extinction ... are exposed to the virus every few years, ...
Breaking Medicine News(10 mins):Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2
... ... appear to continue to resist calling for routine brain monitoring to avoid over medication, especially ... preclude ASA advocating greater patient safety. , ... Newport Beach (PRWEB) February 2, 2010 -- The NFL is giving $1 million ...
... Feb. 1 The Long Beach Library Foundation announces the 9th ... Soloist – A Lost Dream, An Unlikely Friendship, and the Redemptive ... for all ages, are scheduled throughout Long Beach from ... OPENING PUBLIC EVENT - An Evening With Steve Lopez – will take ...
... According ... most common negative patterns in a relationship. Angry individuals may be aware of their problem, ... , ... 1, 2010 -- Personal Power Path announces the launch of an anger management app for ...
... 1 President Obama,s budget, transmitted to Congress this ... Initiative.  Based on projections to continue supporting robust U.S. programs ... -- $16.4 billion is required in FY2011.   ... has an opportunity and must work to get the Obama ...
... , , , DES MOINES, ... lawsuit filed by the Connecticut attorney general, it is ... they need to ensure that they are HIPAA compliant. It is ... the small and medium health care providers, ranging from the local ...
... New research from the University of Pennsylvania School ... resolution by helping them quit smoking. Extended use of a ... recommended by manufacturers boosts the number of smokers who ... backslide into the habit while wearing the patch, according to ...
Cached Medicine News:Health News:Brain Damage: NFL ‘Gets It,' American Society of Anesthesiologists Still Appears ‘Asleep' 2Health News:Brain Damage: NFL ‘Gets It,' American Society of Anesthesiologists Still Appears ‘Asleep' 3Health News:Long Beach Reads One Book 'The Soloist' by Steve Lopez 2Health News:President's Budget for Global Health Far Short of What's Needed - Congress Must Fix 2Health News:President's Budget for Global Health Far Short of What's Needed - Congress Must Fix 3Health News:President's Budget for Global Health Far Short of What's Needed - Congress Must Fix 4Health News:Palisade Systems Comments on the HITECH Lawsuit Filed by the Connecticut Attorney General 2Health News:More smokers kick the habit with extended nicotine patch therapy, Penn research shows 2Health News:More smokers kick the habit with extended nicotine patch therapy, Penn research shows 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: